Pfizer stock ticks up as ViiV exit plan and Novavax vaccine deal keep PFE in focus
Pfizer shares rose 0.8% to $26.10 Thursday after announcing the sale of its 11.7% stake in ViiV Healthcare for $1.875 billion and a licensing deal with Novavax for the Matrix-M vaccine ingredient. The moves come as policy uncertainty over U.S. vaccine guidelines unsettles the sector ahead of Pfizer’s earnings.